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Despite the positive outcome of the recent randomized trial of computed tomography (CT) screening for lung cancer, substantial
implementation challenges remain, including the clear reporting of relative risk and suggested workup of screen-detected nodules. Based on
current literature, we propose a 6-level Lung-Reporting and Data System (LU-RADS) that classifies screening CTs by the nodule with the
highest malignancy risk. As the LU-RADS level increases, the risk of malignancy increases. The LU-RADS level is linked directly to
suggested follow-up pathways. Compared with current narrative reporting, this structure should improve communication with patients and
clinicians, and provide a data collection framework to facilitate screening program evaluation and radiologist training. In overview, category
1 includes CTs with no nodules and returns the subject to routine screening. Category 2 scans harbor minimal risk, including <5 mm,
perifissural, or long-term stable nodules that require no further workup before the next routine screening CT. Category 3 scans contain
indeterminate nodules and require CT follow up with the interval dependent on nodule size (small [5-9 mm] or large [10 mm] and possibly
transient). Category 4 scans are suspicious and are subdivided into 4A, low risk of malignancy; 4B, likely low-grade adenocarcinoma; and
4C, likely malignant. The 4B and 4C nodules have a high likelihood of neoplasm simply based on screening CT features, even if positron
emission tomography, needle biopsy, and/or bronchoscopy are negative. Category 5 nodules demonstrate frankly malignant behavior on
screening CT, and category 6 scans contain tissue-proven malignancies.Resume
En depit des resultats positifs d’un recent essai clinique randomise visant le depistage du cancer du poumon par tomodensitometrie
(TDM), l’instauration ou la diffusion des pratiques de depistage continue de soulever des defis de taille, en ce qui concerne notamment la
classification non equivoque du risque relatif et le bilan propose pour evaluer les nodules deceles par depistage. Apres avoir analyse la
documentation scientifique actuelle, nous avons formule une proposition de systeme de donnees et de declaration a six niveaux, appelee
methodologie LU-RADS (Lung-Reporting and Data System), qui permet de classifier les resultats des tomodensitometries de depistage en
fonction du nodule presentant le risque le plus eleve de cancer du poumon. Dans le cadre de la methodologie LU-RADS, plus les resultats
correspondent a un niveau eleve, plus le risque de malignite est eleve. Le niveau LU-RADS renvoie egalement directement a des recom-
mandations concernant le cheminement de suivi. Ainsi, comparativement aux comptes rendus descriptifs actuels, cette methodologie devrait
ameliorer la communication avec les patients et les cliniciens, et fournir un cadre de collecte de donnees qui facilitera l’evaluation du
programme de depistage et la formation des radiologistes. En resume, dans le cadre de la methodologie LU-RADS, la categorie 1 correspond
aux examens de tomodensitometrie qui ne revelent aucun nodule et exigent simplement du patient qu’il poursuive le programme de depistage
periodique. Les resultats de categorie 2 font etat d’un risque minimal, notamment de nodules de moins de 5 mm, de nodules peri-scissuraux
ou de nodules stables a long terme qui n’exigent aucune autre mesure avant la tenue de la prochaine tomodensitometrie de depistage
periodique. Les resultats de categorie 3 revelent des nodules de nature indeterminee. Une tomodensitometrie de suivi doit alors e^tre realisee,
dans un intervalle qui varie selon la taille du nodule (selon qu’il s’agit d’un petit nodule de 5 a 9 mm ou d’un gros nodule de  10 mm et
possiblement transitoire). Pour leur part, les resultats des examens tomodensitometriques de categorie 4 presentent des caracteristiques* This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
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122 D. Manos et al. / Canadian Association of Radiologists Journal 65 (2014) 121e134suspectes et se subdivisent en trois categories: 4A, faible risque de malignite; 4B, probabilite d’adenocarcinome de bas grade; et 4C,
probabilite de malignite. Les nodules des categories 4B et 4C sont associes a une forte probabilite de neoplasie simplement en raison des
caracteristiques observees par tomodensitometrie de depistage, et ce, me^me si une tomographie par emission de positons (TEP), une
ponction-biopsie ou une bronchoscopie revele des resultats negatifs. Enfin, les nodules de categorie 5 revelent une semeiologie maligne
nettement observable par TDM de depistage, alors que ceux de categorie 6 contiennent des tissus dont la malignite a ete prouvee.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.
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lung cancer in the research setting challenges policy makers to
provide universal access for patients at high risk. Many or-
ganizations, including the U.S. Preventative Services Task
Force, recommend CT screening for patients at high risk
[1e4]. However, implementation of screening outside the
research setting is problematic, and appropriate concerns have
been raised not only in the radiology literature [5,6] but also in
the wider medical field [2,7]. Most radiologists are aware that
lung nodules are common, the vast majority of nodules are
benign, and that not all worrisome lung nodules require the
same workup. However, primary care physicians and the
public in general may not understand these principles. Indeed,
a common perception among patients is that lung nodules are
equivalent to lung cancer [8]. Successful implementation of
screening CT programs will focus on clear communication of
nodule malignant risk by the interpreting radiologist, which
will help to avoid inappropriate referrals, repeated CTs, and
interventions.
In this article, we propose a classification scheme for lung
nodules found on baseline and follow-up screening CTs. The
purpose of this classification is to facilitate communication
with clinicians, provide a framework for data collection and
analysis (including outcomes and quality assurance), and
train radiologists new to screening CT. This classification
scheme incorporates and summarizes existing guidelines and
expert-opinion protocols (such as those produced by the
American Academy of Chest Physicians, the National
Comprehensive Cancer Network, and the Fleischner Society)
and builds upon the strengths of existing screening classifi-
cation systems [9e11]. It is acknowledged that the precise
divisions of lung nodule categories and their corresponding
management may vary among lung cancer screening
programs based on resource availability. Furthermore, the
subcategories may be refined as further evidence emerges.
However, it should be emphasized that the principal aim of
this document is to establish subcategories of nodules that
differ substantially based on management and the likelihood
of malignancy, and to establish a nomenclature that can assist
clinicians and patients.
The Lung Reporting and Data System (LU-RADS) is based
on the successful and widely accepted breast imaging classi-
fication, the BI-RADS (Breast Imaging Reporting and Data
System; American College of Radiology, Reston, VA) [12].
LU-RADS includes 6 categories based on CT appearance,
with an emphasis on serial CT findings. Each category isassociated with a risk of primary lung malignancy and specific
recommendations for workup. This categorization of nodules
allows referring physicians a more sophisticated approach to a
‘‘positive’’ screening CT by emphasizing that different types
of nodules require a different workup. A summary of the LU-
RADS system, including the nodule characteristics for each
category and the reporting and follow-up recommendations, is
provided in Table 1. Because patients may harbor many
nodules, the final recommendation on the CT report is based
on the nodule with the highest risk of malignancy and the
appropriate associated management strategy.
LU-RADS categories and management recommendations
are based on a review of screening CT research in high-risk
patient populations. The possible role of LU-RADS for the
reporting and workup of incidental nodules or for nodules
found in patients who are not at high risk for thoracic ma-
lignancy cannot be addressed in this article due to a lack of
research evidence.
LU-RADS 1Finding: No Nodule
Management: Return to Regular Screening
This category applies to screening CTs in which no
nodules are seen. Although the likelihood of lung malig-
nancy in the next 2 years is very low, malignancy may arise
in a nodule present but not detected, an interval nodule, or a
malignancy not detectable by screening [13,14].Reporting and Management of LU-RADS 1 NodulesPatients and physicians need to be made aware of the
limitations of screening CT and should be reminded that,
even after a category 1 CT, the development of concerning
symptoms (eg, unexplained hemoptysis) should prompt
clinical evaluation. The report also should include a recom-
mendation to return to regular screening and specific infor-
mation regarding the timing of the next screening CT.
LU-RADS 2Finding: Benign Nodule
Management: Return to Regular Screening
This category includes nodules with an extremely high
likelihood of benign etiology. For the current state of
Table 1
LU-RADS summary (for use in screen detected nodules in patients at high risk for lung cancer)
Examples Comments
1. No nodule Return to regular screening; risk of malignancy related to interval cancer, cancer not
detectable by CT, and nodules present but not identified
2. Benign nodule Nodules < 5 mm; perifissural opacities; benign calcification hamartoma Safe to return to annual screening; risk of malignant diagnosis before next screen
very low; no benefit for earlier follow upCore biopsy benign; solid stable for 2 y; subsolid stable for 5 y, round atelectasis
3. Indeterminate;
requires
serial LDCT
Small: 5-9emm nonenlarging nodule with <2 y (solid) or <5 y stability
(subsolid)
Follow up as per schedule (Fleischner or screening-specific guidelines; note, some suggest
following up new nodules more closely than baseline nodules)
Large: baseline or new nodule  10 mm with any possibility of transient
inflammatory process, eg, new or baseline subsolid nodules 10 mm, or
eg, inflammatory clinical or CT features (rapid development, multifocal,
satellite nodules, air bronchogram, or ground-glass border)
Follow up in 6-12 wk to exclude transient inflammatory process; no improvement is
worrisome (reclassify into category 4)
4. Suspicious 4A. Low risk of malignancy; solid nodule (10 mm) with benign features
but CT not definitive for category 2; eg, well-defined roughly spherical nodule
likely hamartoma or granuloma
Review all possibly relevant prior imaging; needs workup; at minimum, follow-up
at 3 mo; refer; other possibilities: core biopsy, PET (negative PET is reassuring in
this category; value of positive PET dependent on rate of granulomatous disease)
4B. Likely in situ or minimally invasive adenocarcinoma; nonresolving subsolid
opacity  10 mm (with solid component  5 mm)
Risk of preinvasive or minimally invasive disease high; refer; surgical biopsy and/or
resection vs annual screen if stable; PET and biopsy are not routinely recommended
(high false negatives)
4C. Likely malignant Risk of malignancy very high in high-risk screening population
1. Worrisome persistence; nonresolving part solid nodule  10 mm (solid portion > 5 mm) Refer
2. Worrisome change; malignant growth rate in solid nodule or portion Benefit of PET is in staging not diagnosis
3. Worrisome baseline; lobulated or spiculated entirely solid nodule 10 mm
with no inflammatory CT or clinical features, no ground-glass border
Negative PET, bronchoscopy, or biopsy is discordant and should prompt multidisciplinary
review
5. Malignant by CT Invasion of chest wall or mediastinum. As per 4C
6. Tissue malignant Eg, positive FNA, core, bronchoscopy, or surgical resection False-positive results possible but very rare with FNA; assuming that the patient remains
a treatment candidate and no regular CT for disease surveillance, continued screening is
recommended
CT ¼ computed tomography; FNA ¼ fine needle aspiration; LDCT ¼ low dose CT; LU-RADS, Lung-Reporting and Data System; PET ¼ positron emission tomography.
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calcification (entirely calcified, a complete calcified ring, or
central calcification); solid nodules 5 mm that demonstrate
no orminimal growth over at least a 2-year period and subsolid
nodules 5 mm that demonstrate no growth over at least a
5-year period [15]; perifissural opacities with benign features
(ie, smooth well-defined subcentimetre solid nodules located
along a fissure and with an oval, lentiform, or polygonal shape
[Figure 1] [16,17]); fat-containing nodules that meet criteria
for hamartoma (40 to120 HU in at least 8 voxels) [18,19];
round atelectasis (abuts pleural surface and is associated with
volume loss, pleural abnormality, and bronchovascular
swirling) [20]; and nodules with a specific benign diagnosis
obtained by core biopsy. The category also includes nodules of
any density that measure <5 mm (approximately 60 mm3)
[21e23]. The unifying principle for this diverse list of opacities
is that there appears to be no benefit for workup before the
next screeningCT.Ground-glass nodules smaller than 5mmare
often transient and inflammatory. When persistent, these
nodules are often foci of atypical adenomatous hyperplasia and
do not require follow-up prior to the next screening CT [17].
Analysis of solid nodules <5 mm has shown a malignant
rate of 0.0%-0.2% after 1 or 2 years of follow-up [21,24,25].
The long-term malignant rate of these tiny nodules is less
well documented. In Milan, a 4-year study of 1035 smokers
at high risk found that 3 of 238 nodules 5 mm on the
baseline examination were eventually determined to be ma-
lignant [26]. Even if a <5-mm nodule is malignant, there
appears to be no benefit in follow-up earlier than 1 yearFigure 1. Perfissural opacity. Axial baseline computed tomography,
demonstrating a 10  6-mm, solid, well-defined nodule (arrow) along the
path of the right major fissure in a patient who was a high-risk smoker. This
is characterized as Lung Reporting and Data System 2 (benign nodule).because growth is difficult to reliably detect in small nodules,
and 1 year later the malignancies remain T1N0
[14,21,24,26,27]. Based on data from the National Lung
Screening Trial, the Dutch-Belgian Randomized Lung Can-
cer Screening Trial (NELSON), the Mayo Clinic study and
the British Columbia Cancer Agency study, the risk of a lung
cancer diagnosis within 2 years of a category 1 or 2 exam-
ination is estimated at 0.2%-0.3% [22,25,28e30] and is
largely influenced by the underlying risk of the patient for
lung cancer.Reporting and Management of LU-RADS 2 NodulesPatients and referring physicians should be made aware
that, even though a nodule is present, the likelihood of a lung
cancer diagnosis in the next 2 years is extremely low. In fact,
the risk of malignancy for a screening participant at high risk
is now much lower than immediately before the CT. The CT
report should state that referral or any other workup is not
indicated. Greater care must be taken, however, if a
screening program includes patients with prior malignancy.
For a screening participant at risk for pulmonary metastases
(such as survivors of invasive breast cancer), an earlier
follow-up may be necessary for tiny solid nodules. The
limitations of screening, as discussed for category 1, should
be made clear. The report also should include a recommen-
dation to return to regular screening and specific information
regarding the timing of the next screening CT.
LU-RADS 3Finding: Indeterminate Nodule
Management: Follow-up Low-Dose CT
Category 3 nodules require follow-up CT before risk can
be determined. A more advanced workup should be delayed
until the behavior of the nodule on serial CT can be assessed.
This category can be divided into new or nonenlarging small
nodules (5-9 mm, approximately 60-500 mm3) (S) and large
nodules (10 mm or 500 mm3) with any possibility of a
transient inflammatory process (L). In both situations, the
follow-up CT can be performed with the dose-reducing
strategies of screening CT. Some screening centres may
decide to limit radiation by confining the repeat CT to the
area of interest.LU-RADS 3S. Small Nodules That Require Follow-upThis includes nodules 5-9 mm that have not yet demon-
strated 2 years of stability (for solid nodules) or 5 years of
stability (for subsolid nodules). Several follow-up schedules
have been published, including the Fleischner guidelines
for solid nodules [31] and subsolid nodules [32]. Some
screening-specific schedules, including those used by the
International Early Lung Cancer Action Program (I-ELCAP)
and NELSON, follow up new nodules on repeated annual
scans more closely than those nodules seen on the baseline
Figure 2. Progressively enlarging solid nodule. (A) Baseline screening computed tomography (CT), demonstrating a solid, 6  5-mm nodule in the right lower
lobe (arrow). This is a Lung Reporting and Data System (LU-RADS) 3S nodule (indeterminate, requires serial CT). No enlargement was demonstrated on
follow-up screening-type CT 3 months later (not shown), and the nodule remains category 3. (B) Follow-up CT 12 months after baseline, showing enlargement
to 9  6-mm and the nodule (arrow) becomes LU-RADS 4C (likely malignant). The team was reluctant to proceed with surgery for a subcentimetre nodule, and
a continued follow-up low-dose CTwas performed. (C) The last CT before resection, 26 months after baseline examination, demonstrating further enlargement
to 10  9 mm (arrow). Resected specimen revealed stage IA adenocarcinoma.
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aggressive and grow more quickly than prevalent malig-
nancies [11,33]. LU-RADS is not designed to replace these
follow-up schedules but to work with them. It is understood
that different screening programs may adopt different follow-
up schedules. Nodules remain in this category until they
demonstrate sufficient stability to be reclassified into the LU-
RADS 2 category or until they demonstrate worrisome
change. If a solid nodule enlarges or a ground-glass nodule
increases in density or grows to at least 10 mm, then the
nodule becomes worrisome and should be reclassified as LU-
RADS 4B or 4C (Figure 2).
Rates of malignancy for these small nodules are an area of
growing research. A recently published risk model allows
physicians to assign nodule risk by using patient de-
mographics (including age) and nodule characteristics
(including size and density) [34]. Data from the British
Columbia Cancer Agency places the malignant rate at 1% for
nodules in the 4-10 mm size [25]. The National Lung
Screening Trial found a 2.4% risk of lung cancer in nodules
between 7 and 10 mm but only a 0.3% risk in nodules be-
tween 4 and 6 mm [30]. Regardless of baseline size, once
growth is identified, the risk increases substantially. By
emphasizing the importance of serial CT for evaluation of
LU-RADS 3S type nodules, the NELSON screening trial was
able to reduce the percentage of positive screening scans to2.6% relative to the 24.2% rate in the National Lung
Screening Trial [23,29].
Based on analysis of screen-detected nodules, a volume-
doubling time of less than 400 days in a solid nodule is
generally considered consistent with a malignant growth rate
[35]. Ground-glass neoplasms grow more slowly. Malignant
nodules can grow irregularly with 1 part of the nodule
remaining stable and other parts enlarging (Figure 3). In
comparison with the most-remote CT images available,
visual assessment of the proximity to adjacent structures and
either multiplanar imaging or volumetric analysis may allow
more confident identification of subtle growth. Because
malignancies may occasionally regress in size transiently, a
mild decrease in size on a single CT may not allow confident
diagnosis of a benign etiology, and further follow-up as
clinically indicated is recommended [36].Reporting and Management of LU-RADS 3S NodulesPatients and referring physicians should be made aware
that serial CT is the best way to evaluate these small non-
enlarging nodules. Many follow-up schedules are available,
including those released by the Fleischner Society [31,32].
The timing and frequency of follow-up is primarily influ-
enced by size, with larger nodules in this group requiring
shorter-interval follow-up CTs. The optimal timing interval
Figure 3. Subtle growth in adenocarcinoma. (A) A 11  5-mm (mean, 8 mm) solid nodule is seen on screening baseline computed tomography (CT) and is
characterized as LungReporting andData System (LU-RADS) 3S (indeterminate; requires serial CT). (B) Follow-up screening typeCTwas performed at 3months
(not shown) and showed no enlargement. CT at 9 months, showing no change in the maximum dimension. Careful inspection demonstrated subtle growth pos-
teriorly (arrow), and the nodule is now classified as LU-RADS 4C (likely malignant). Pathology demonstrated invasive adenocarcinoma with lepidic features.
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research on existing lung cancer screening cohorts. For some
nodules, the follow-up interval will coincide with the
screening interval. Due to the low likelihood of malignancy,
the risk of harm, and the difficulty with obtaining diagnostic
results, additional workup of these small nodules is not
recommended. Reports should note the low risk of malig-
nancy and include a specific recommendation regarding the
timing of the next CT.LU-RADS 3L. Large Nodules That Require Follow-upThis includes all new or baseline nodules that measure at
least 10 mm (approximately 500 mm3) for which there are
any CT or clinical features that suggest any possibility of aFigure 4. Transient solid nodule. Baseline screening computed tomography (CT)
mm solid nodule in the left upper lobe. The nodule contains air bronchograms a
(indeterminate; requires follow-up CT). (B) Follow-up CT 8 weeks later, demontransient inflammatory process. Radiologists should strongly
consider using this category for a new large solid nodule not
seen, even in retrospect, on the last screening examination
and for any new or baseline large subsolid nodule. The
purpose of this category is to help ensure that transient in-
flammatory processes are not misidentified as malignant.
Many guidelines suggest that biopsy, positron emission to-
mography (PET), or resection be considered for nodules that
measure at least 10 mm [1,31]. However, for new or baseline
nodules in which an inflammatory etiology is possible, short-
interval screening-type CT often demonstrates resolution
(Figures 4, 5). A large (10 mm) nodule that suddenly ap-
pears between annual screening CTs must have a short
volume-doubling time (<30 days) and, therefore, is more
likely to be a transient nodule than an equivalent-size noduleof a patient who was high risk and asymptomatic, demonstrating a 27  28-
nd should be classified as Lung Reporting and Data System (LU-RADS) 3L
strating near-complete resolution (LU-RADS 1).
Figure 5. Transient spiculated nodule in a patient with a recent history of pneumonia. (A) Baseline computed tomography (CT) in a patient who was
asymptomatic, demonstrating a solid spiculated 15  10-mm nodule in the left lower lobe (arrow). The patient was found to have had consolidation in the left
lower lobe on a chest radiograph obtained for cough and fever 3 months before the baseline CT, and, therefore, the nodule was classified as Lung Reporting and
Data System (LU-RADS) 3L (indeterminate; requires serial CT). (B) Follow-up 6 weeks later, demonstrating marked size decrease (arrow). Classification is
now LU-RADS 2.
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screening research suggest that short-interval follow-up of
new large nodules seen on annual screens can avoid biopsy
or other workup [14,38]. This strategy for large nodules has
also been evaluated on baseline scans in the Canadian arm of
I-ELCAP. In this study, 95% of patients with a positive
baseline scan had short-interval follow-up CT, and 26%
demonstrated resolution or decrease in nodule size [39],
which confirmed the transient inflammatory nature of these
indeterminate large nodules.
This concept is particularly important for subsolid nod-
ules and nodules with an indistinct border. From 44%-70%
of screen-detected subsolid nodules resolve [37,40]. The
Fleischner Society guidelines for subsolid nodules highlights
this fact and recommends that all new or baseline subsolid
nodules have a short-interval follow-up, even when they
measure 10 mm [32]. If these nodules demonstrate no
improvement on subsequent examinations, the likelihood of
malignancy is much higher (see LU-RADS 4B).
The decision to place a large nodule (10 mm or 500
mm3) into LU-RADS category 3 may be difficult. The
likelihood that a nodule is transient is increased if it is new,
has indistinct or ground-glass margins, is at least partially of
ground-glass density, is one of many new nodules, is clus-
tered, is associated with other CT features of inflammation
(eg, multifocal or tree-in-bud opacities), or if there is a his-
tory of respiratory infection in the past 3 months (Figure 5)
[37,38,40]. A recent history of respiratory symptoms,hospital admission, emergency department visit, infectious
symptomatology, and chest pain should be reviewed and
made available to the reporting radiologist. Screening centres
cannot rely on accurate requisitions and must obtain clinical
information directly from the patient.Reporting and Management of LU-RADS 3L NodulesA 6-12eweek follow-up interval has been suggested
based on the assumption that 6-12 weeks will be sufficient to
allow most inflammatory processes time to at least partially
resolve but not so long as to substantially increase the risk
that a lung malignancy will significantly progress in stage. A
PET can be misleading and should be specifically avoided in
this category until follow-up CT has been preformed. An
active inflammatory process, even if asymptomatic, may
show high levels of fluorodeoxyglucose (FDG) avidity. For a
subsolid nodule, a high level of FDG avidity is more often
demonstrated in benign inflammatory processes than in
malignant ones [41]. Consider that a large new nodule has a
higher likelihood of a false-positive PET result (due to the
possibility of active inflammatory disease) than the same size
nodule that has grown over the past year.
With the advent of high-quality thin-section CT and the
continuous improvements in dose reduction, the value of
serial screening-type low-dose CT as a diagnostic tool, rather
than merely a screening tool, has received some attention
[42-44]. Although serial CT cannot replace other workup
Figure 6. Lung Reporting and Data System (LU-RADS) 4A nodule (suspicious, low risk of malignancy). (A) Unenhanced computed tomography (CT),
demonstrating a 17-mm, well-defined, roughly spherical, solid nodule with minimal lobulation. The nodule was thought to represent a hamartoma but macroscopic
fat could not be confirmed by CT. The lesion was categorized as LU-RADS 4A (suspicious; low risk of malignancy). (B) Fluorodeoxyglucose positron emission
tomography (PET), demonstrating no uptake. The negative predictive value of the PET for a low-risk solid nodule in a patient who is high risk is very good. In
conjunction with the surgeon, the patient chose not to have the nodule resected. After 2 years of stability, it is reclassified as LU-RADS 2 (benign nodule). This
figure is available in colour online at http://carjonline.org/.
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lower-radiation approach to the diagnostic evaluation of
screen-detected nodules. If short-interval follow-up fails to
demonstrate any resolution, then the large nodule becomes
worrisome and can be reclassified into category 4. If the
opacity decreases in size but does not resolve, then the
radiologist may choose to follow up the lesion again before
returning to the regular screening interval.LU-RADS 4Finding: Suspicious Nodule
Management: Depends on Subcategory
See 4A, 4B, and 4C.LU-RADS 4AFinding: Suspicious; Low Risk of Malignancy
Management: Workup
This category includes large solid nodules (10-25 mm),
with benign but not definitive CT features, such as a well-
defined roughly spherical nodule without microlobulations
(Figure 6). Examples include a hamartoma without macro-
scopic fat or a noncalcified granuloma. In this category,
every effort possible should be made to obtain prior imaging
because this may establish a reassuring chronic nature.
Depending on the location of the nodule, prior plain films or
cross-sectional imaging not only of the chest but also of the
abdomen, neck, or shoulder, for example, may reveal the
nodule. Nodules in this category may grow; a volume-
doubling time of more than 400 days for a solid nodule is
generally regarded as consistent with benign disease [35]. It
should also be noted that metastatic disease (especially sol-
itary deposits) can demonstrate a similar appearance on a
single CT; screening centres should be aware of any prior
diagnoses of malignancy.Reporting and Management of LU-RADS 4A NodulesThese nodules can pose a diagnostic challenge to the
radiologist. Although PET may be of limited diagnostic use
for other nodule categories, the negative predictive value of
PET (ie, the likelihood that a negative result is correctly
negative) is high for solid nodules in this category because the
pretest probability of malignancy based on the CT features is
low (Figure 6) [19]. The positive predictive value of PET will
depend on the local rate of granulomatous disease, a common
cause of false-positive examinations [44,45]. Even if workup
is reassuring and suggests a benign etiology, continued serial
CT is recommended. Once minimal or no growth is confirmed
at the 2-year follow-up, these large nodules can be reclassified
as LU-RADS 2. Tissue diagnosis is another option in this
category, and a core biopsy is preferred because it has a higher
likelihood of providing a specific benign etiology compared
with fine needle aspiration [46]. Core biopsy with a specific
benign etiology can allow the nodule to be classified as benign
(LU-RADS 2).
Patients with category 4A nodules often require referral
(pulmonologist or thoracic surgeon, depending on local
practices). Many of these nodules will not require surgery,
but the decision process should allow input from the patient
after a complete discussion of the risks and benefits. In
addition, a more thorough clinical assessment may reveal a
benign etiology. The rate of malignancy in this category will
be dependent on the local rate of granulomatous disease and
the results of the workup.LU-RADS 4BFinding: Suspicious; Likely In Situ or Minimally
Invasive Adenocarcinoma
Management: Surgical Biopsy or Follow-up;
Depending on the Patient
Nodules in this category measure 10 mm (>500 mm3),
are persistent (fail to resolve or improve on follow-up CT),
Figure 7. Persistent ground-glass opacity. (A) A 17-mm pure ground-glass opacity on baseline computed tomography (CT) is categorized as Lung Reporting
and Data System 3L (indeterminate; requires serial CT). (B) Three months later, the CT shows no change, and the nodule becomes category 4B (likely low-
grade adenocarcinoma). This 68-year-old woman underwent microcoil-guided resection. Pathology demonstrated stage IA adenocarcinoma in situ.
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glass density with a solid portion that measures not more
than 5 mm. Although these nodules have a neoplastic rate of
75%-80% [47e49], they often represent foci of preinvasive
or minimally invasive disease; persistent pure ground-glass
nodules have a high likelihood of adenocarcinoma in situ
(Figure 7) and part-solid nodules with a solid component that
measures 5 mm have a high likelihood of minimally
invasive adenocarcinoma [50]. When resected, the 5-year
survival rate for these neoplasms is near 100% [48,51,52].
The natural history of these lesions is less well understood,
but certainly the slow growth rate suggests a much less
aggressive behavior than other forms of lung cancer [53].
When multiple persistent ground-glass nodules are present,
these likely represent multiple primary lesions rather thanFigure 8. Enlarging ground-glass opacity. (A) Baseline computed tomography (CT
Reporting and Data System (LU-RADS) 3S (indeterminate; requires serial CT
(LU-RADS 4B, likely low-grade adenocarcinoma). Segmentectomy demonstratemetastatic disease [54]. Two years of stability does not
confirm benign etiology in this category [55e57]. Ground-
glass neoplasms grow slowly, often with a doubling time of
>600 days (Figure 8) [58,59]. A comparison should be made
to the most recent prior CT and the most remote CT available.Reporting and Management of LU-RADS 4B NodulesWorkup of these lesions, due to their lack of aggressive
nature, may appear counterintuitive to those not familiar with
screening. Neoplastic lesions in this category are unlikely to
demonstrate high levels of FDG avidity [60e62]. PET is not
indicated for staging purposes in this category because sub-
solid nodules with a solid portion that measures not more
than 5 mm are highly unlikely to demonstrate metastases), demonstrating an 8-mm ground-glass opacity (arrow) categorized as Lung
). (B) CT obtained 5 years later, showing enlargement (arrow) to 14 mm
d adenocarcinoma in situ.
Figure 9. Subsolid nodule, demonstrating worrisome change. (A) An annual computed tomography (CT), demonstrating a persistent 14-mm pure ground-glass
opacity (arrow). This is a Lung Reporting and Data System (LU-RADS) 4B nodule (likely low-grade adenocarcinoma). The patient was not referred to surgery
and did not return for recommended follow-up. (B) CT 3 years later, showing the nodule has enlarged to 34 mm and contains a 12 mm solid portion. The nodule
is now classified as LU-RADS 4C (likely malignant).
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taneous sampling of subsolid nodules with a solid portion
that measures 5 mm [63] because the yield is low [64]. The
Fleischner Society guidelines recommend percutaneous core
biopsy in subsolid nodules only to assist nonsurgical treat-
ment [32].
Routine resection of category 4B nodules has been criti-
cized for contributing to lead time bias and overdiagnosis of
indolent cancer in screening trials [65]. Although these neo-
plasms grow slowly, they can progress to invasive adenocar-
cinoma (Figure 9) [66,67]. Regardless of the controversy
regarding management of category 4B nodules, detection of
these nodules should prompt referral to thoracic surgeon or
pulmonologist/respirologist. Ideally, treatment and manage-
ment decisions will be made as a team and in conjunction
with the patient. Wedge resection may be an option for
ground-glass nodules that measure >10 mm, especially when
enlarging. Microcoil localization may assist resection because
these nodules are often difficult to identify intraoperatively
[68]. Patients who are not to receive initial resection should
have yearly follow-up with a screening-type CT to monitor
for an increase in overall size and in size of the solid
component. Nodules with a growing solid component are
more likely to be aggressive and should be reclassified into
category 4C [69e71].LU-RADS 4CFinding: Suspicious; Likely Malignant
Management: Confirm, Stage, and Treat
Category 4C nodules have CT or serial CT features that
are very worrisome for invasive malignancy. These nodulesare sufficiently worrisome that negative FNA, negative
bronchoscopy, negative dynamic enhanced CT, and/or
negative PET are discordant, and results should be treated
with caution. This concept will be recognizable to those
familiar with the BI-RADS category 4C. Worrisome CT
features include (1) worrisome persistence: a lack of any
improvement after short-interval follow-up of a large (10
mm) part-solid nodule with a solid portion of at least 5 mm;
(2) worrisome growth: malignant growth rate of a solid
nodule or solid portion of a nodule (Figures 2, 3, 9); or (3)
worrisome baseline: a baseline well defined (ie, no ground-
glass border) lobulated or spiculated solid nodule that mea-
sures at least 10 mm (500 mm3) with no CT features or
clinical possibility of inflammatory disease (Figure 10).
Nodules in this category do not have benign CT features (ie,
are not category 2 or 4A). Category 4C nodules in screening
patients at high risk are almost always malignant. In areas
endemic for granulomatous disease or fungal infection, the
rate of malignancy in this category will be lower [44,45].Reporting and Management of LU-RADS 4C NodulesCategory 4C nodules should prompt urgent referral and
definitive workup. However, negative PET-CT, negative
FNA, and negative bronchoscopy may represent false-
negative findings in this category, and any discordant re-
sults should prompt discussion. The primary benefit of PET
for these screen-detected high-risk nodules in patients at high
risk is in staging, not diagnosis [72,73]. Another possible
benefit of PET in this category is in the evaluation of the
patient with multiple part-solid nodules thought to represent
multiple primary malignancies. PET can assist surgical de-
cisions by identifying the more aggressive of the lesions [60].
Figure 10. Worrisome baseline. Baseline computed tomography in a patient
at high risk and asymptomatic, demonstrating an entirely solid, lobulated,
20-mm nodule with no ground-glass component or border. The nodule was
classified as Lung Reporting and Data System 4C (likely malignant). Tissue
diagnosis was positive for nonesmall-cell lung carcinoma.
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peripheral screen detected nodules [28].
If percutaneous biopsy is to be performed for a part-solid
lesion, then the solid portion should be targeted. The solid
portion in a malignant part-solid nodule often represents
areas of invasive adenocarcinoma in an otherwise in situ
neoplasm [54,57]. Prognosis is better predicted by thepercentage of the nodule that is solid and by the size and
growth of the solid portion rather than the size and growth of
the nodule as a whole [69e71]. Therefore, for part-solid
nodules, reports should include size and growth informa-
tion both for the nodule as a whole and the solid component.
A comparison should be made both to the most recent prior
CT and to the most remote CT available.
LU-RADS 5Finding: Malignant by CT
Management: Confirm, Stage, and Treat
Category 5 lesions demonstrate frankly malignant behavior
by CT. Examples include lesions that are invading the chest
wall or the mediastinum. The risk of malignancy is very high
for this category. Rarely, aggressive infectious processes or
inflammatory infiltrative processes (such as actinomycosis or
fibrosing mediastinitis) can result in a similar CT appearance.
However, in the high-risk screening population, category 5
lesions will overwhelmingly represent malignancy.Reporting and Management of LU-RADS 5 NodulesPrompt referral or discussion with thoracic surgery or pul-
monologist/respirologist is recommended so that resectability
and options for tissue diagnosis can be assessed as soon as
possible. If PET is obtained for any reason, then negative results
should be considered discordant with the CT findings, and the
case should be discussed. For unresectable tumours, tissue
diagnosis is often necessary before radiation treatment or
chemotherapy. Negative tissue sampling or negative bronchos-
copy would be considered discordant and should be discussed.
LU-RADS 6Finding: Tissue-Proven Lung Malignancy
Management: Stage and Treat
Category 6 lesions show positive results on bronchoscopy,
percutaneous tissue sampling, or surgical resection.
Although patients with category 6 nodules would no longer
be considered screening participants, the category is included
to help facilitate data analysis. Many of these patients will
have follow-up imaging, and a portion will not undergo
surgical resection. In addition, because these patients have an
elevated risk of a second primary bronchogenic cancer [74],
they should remain in the screening program if they remain
candidates for treatment and if they are not already receiving
regular follow-up CT. Continued screening after resection is
especially beneficial for patients who have had definitive
treatment of early stage disease, particularly in situ or
minimally invasive adenocarcinoma.Reporting and Management of LU-RADS 6 NodulesThese patients require definitive staging and treatment.
Figure 11. Effect of volume averaging on perceived nodule density. (A) Unenhanced computed tomography, with 1-mm slice thickness reconstructed axial
images, demonstrating a 4-mm solid nodule (arrow). (B) When the same source data are reconstructed at 5-mm slice thickness, the nodule appears as ground
glass (arrow).
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Nodule size is measured on high spatial frequency images
(lung and/or bone algorithm) and is defined as the mean of
the longest diameter and its perpendicular diameter on a
single transverse CT image. Diameter differences <2 mm
have been shown to be unreliable and do not allow confident
identification of nodule growth or regression [75]. Whereas
volumetric analysis can have some practical limitations, it
has been shown to be more accurate and reproducible than 2-
dimensional measurements [76] and provides superior data
for calculation of nodule doubling time [23]. With the 512 
512 viewing matrix of current CT scanners and a full-body
field of view (eg, 30 cm), the resultant pixel size
(0.68 mm) is too large to allow accurate submillimetre
measurement. Stability cannot be assessed unless all prior
CTs, most importantly, the earliest CT, are reviewed. It
should be noted that compared with noncontrast examina-
tions, stable nodules on intravenous contrast-enhanced im-
ages may appear to have grown compared with previous
noncontrast enhanced images [77].
A 1- or 2-mmesection thickness reconstruction is essen-
tial to minimize volume-averaging effects. Thin section
improves the evaluation of nodule growth, nodule density,
and changes in nodule density (Figure 11). Thin-section
collimation (1-2 mm) intermediate spatial frequency im-
ages (standard and/or mediastinal algorithm) provide
improved measurement of the solid component of nodules
and allows identification of focal fat and calcification that
may be missed on thick sections. Due to image noise effects,
CT density measurements of fat and calcification should be
obtained by using intermediate spatial frequency images.
Changes in scanner kVp and the beam-hardening effects of
shields (breast and thyroid) may lead to inaccuracies in
density measurements anywhere in the field of view [78,79].
It also must be emphasized that, given the prebooked na-
ture of screening CTs, clinical information on the requisition
may be out of date. Clinical information obtained from the
patient at the time of the CT regarding any recent respiratory,infectious, or inflammatory symptoms; history of malignancy;
history of radiation to the lung; and prior lung imaging may be
highly useful. Finally, every point of contact with the patient
should be used to assist or support smoking cessation.Conclusion
Given the frequency of pulmonary nodules in the high
lung-cancer risk CT screening population, there is substantial
risk of incomplete communication and consequent nodule
overinvestigation. The aim of LU-RADS is to provide a more
standardized and informative CT report by classifying nodules
into 1 of 6 categories, with associated management strategies.
The evolution of high-quality thin-section CT imaging allows
the LU-RADS classification to highlight the important diag-
nostic role of nodule change on serial low-dose screening CTs.
Thus, the information obtained by using biopsy, PET, bron-
choscopy, and intravenous contrast-enhanced CT adds to
rather than supersedes that available from the screening CT
data set. Improved classification of screen-detected nodules by
using LU-RADS should reduce the costs and risk of unnec-
essary workup and improve the cost-effectiveness of proposed
lung cancer screening programs.Acknowledgements
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